IGN 201Alternative Names: IGN-201; MyVaccine®
Latest Information Update: 05 Nov 2009
At a glance
- Originator igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-AG
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 05 Nov 2009 Discontinued - Preclinical for Cancer in Austria (unspecified route)
- 29 Mar 2005 igeneon Krebs Immuntherapie Forschungs und Entwicklungs AG has been acquired by Aphton Corporation
- 07 Aug 2002 Preclinical trials in Cancer in Austria (unspecified route)